National service framework for coronary heart disease. Ambiguities need to be clarified.
作者信息
Lloyd-Mostyn R
出版信息
BMJ. 2000 Sep 9;321(7261):634.
Abstract
摘要
相似文献
1
National service framework for coronary heart disease. Ambiguities need to be clarified.冠心病国家服务框架。歧义需要澄清。
BMJ. 2000 Sep 9;321(7261):634.
2
Optimizing the prescription of statins after an acute coronary syndrome: the influence of coronary angioplasty and total cholesterol levels.优化急性冠状动脉综合征后的他汀类药物处方：冠状动脉血管成形术和总胆固醇水平的影响
Cardiovasc Drugs Ther. 2001 Nov;15(6):559-60. doi: 10.1023/a:1013732124399.
3
Summaries for patients. Risk factors and treatment in women with coronary artery disease.患者摘要。冠心病女性的危险因素与治疗
Ann Intern Med. 2003 Jan 21;138(2):I10. doi: 10.7326/0003-4819-138-2-200301210-00001.
4
5
Management of acute coronary syndromes.急性冠状动脉综合征的管理
Am J Respir Crit Care Med. 2001 Sep 15;164(6):917-22. doi: 10.1164/ajrccm.164.6.2101047.
6
Status of secondary prevention in patients undergoing coronary revascularization.接受冠状动脉血运重建患者的二级预防状况
Am J Cardiol. 2001 May 15;87(10):1203-6: A7. doi: 10.1016/s0002-9149(01)01496-5.
7
[Cardiovascular protection and prevention in patients with cardiac conditions and diabetes].
Presse Med. 2005 Oct 22;34(18):1295-8. doi: 10.1016/s0755-4982(05)84176-4.
8
Long waiting list for by-pass surgery.心脏搭桥手术的等候名单很长。
Age Ageing. 2003 May;32(3):360. doi: 10.1093/ageing/32.3.360.
9
Pharmacological interventions to manage coronary heart disease.
Nurs Times. 2003;99(27):48-9.
10
Should elderly individuals who frequently nap take beta-blockers and/or aspirin?经常午睡的老年人应该服用β受体阻滞剂和/或阿司匹林吗？
Arch Intern Med. 2000 Mar 13;160(5):710; author reply 711-2. doi: 10.1001/archinte.160.5.710.
引用本文的文献
1
Advances in the treatment of ST Elevation Myocardial Infarction in the UK.英国ST段抬高型心肌梗死治疗的进展
JRSM Cardiovasc Dis. 2022 Feb 16;11:20480040221075519. doi: 10.1177/20480040221075519. eCollection 2022 Jan-Dec.
本文引用的文献
1
Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population.一级预防的冠心病和心血管疾病风险评估：1995年苏格兰健康调查人群中一种新的谢菲尔德表格的验证
BMJ. 2000 Mar 11;320(7236):671-6. doi: 10.1136/bmj.320.7236.671.
2
Heart disease framework aims to cut deaths in england.心脏病防治框架旨在降低英国的死亡率。
BMJ. 2000 Mar 11;320(7236):665.
3
Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.英国关于临床实践中冠心病预防的联合建议。英国心脏病学会、英国高脂血症协会、英国高血压学会，获英国糖尿病协会认可。
Heart. 1998 Dec;80 Suppl 2(Suppl 2):S1-29.
4
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.普伐他汀对冠心病及初始胆固醇水平范围广泛的患者心血管事件和死亡的预防作用。
N Engl J Med. 1998 Nov 5;339(19):1349-57. doi: 10.1056/NEJM199811053391902.
5
Cholesterol: how low is low enough?胆固醇：多低才算足够低？
BMJ. 1998 Aug 15;317(7156):425-6. doi: 10.1136/bmj.317.7156.425.
6
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.普伐他汀对胆固醇水平正常的心肌梗死患者冠状动脉事件的影响。胆固醇与再发事件试验研究人员。
N Engl J Med. 1996 Oct 3;335(14):1001-9. doi: 10.1056/NEJM199610033351401.
7
Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S).斯堪的纳维亚辛伐他汀生存研究（4S）中的基线血清胆固醇水平及治疗效果
Lancet. 1995 May 20;345(8960):1274-5.
Zotero 插件